Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients

Ali Abouelghar, Reem Hasnah, Ghina Taouk, Mohamad Saad, Manale Doldur

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Natural killer (NK) cells are lymphocytes of the innate immune system that have potent cytotoxic activity against tumor cells. NK cell recognition and activity towards cancer cells are regulated by an integrated interplay between numerous inhibitory and activating receptors acting in concert to eliminate tumor cells expressing cognate ligands. Despite strong evidence supporting the role of NK cells in breast cancer (BC) control, BC still develops and progresses to form large tumors and metastases. A major mechanism of BC escape from NK immunity is the alteration of the expression of NK receptor ligands. The aim of this study was to determine whether NK receptor ligands' mRNA expression might influence prognosis in BC patients and whether these effects differ by molecular subtypes and clinicopathological features. Methods: We used the KM plotter platform to analyze the correlation between mRNA expression of 32 NK receptor ligands and relapse-free survival (RFS) and overall survival (OS) in 3951 and 1402 BC patients, respectively. The association with tumor subtypes and clinicopathological features was determined. BC samples were split into high and low expression groups according to the best cutoff value and the two patient cohorts were compared by Kaplan-Meier survival plots. The hazard ratios with 95% confidence intervals and log rank P values were calculated and FDRadjusted for multiple testing correction. The data was considered to be statistically significant when FDR-adjusted P value < 0.05. Results: High mRNA expression of around 80% of ligands for NK activating and inhibitory receptors associated with better RFS, which correlated with longer OS for only about half of the NK-activating ligands but for most NK-inhibitory ligands. Also, five NK-activating ligands correlated with worse prognosis. These prognostic values were differentially associated with the BC clinical criteria. In addition, the favorable prognostic influence of NK-activating ligands' upregulation, as a whole, was mainly significantly associated with HER2-positive and basal-like subtypes, lymph node positive phenotype, and high-grade tumors. Conclusions: NK receptor ligands appear to play an important role in defining BC patient prognosis. Identification of a group of patients with worse prognosis expressing high levels of NK-activating ligands and low levels of NK-inhibitory ligands makes them ideal potential candidates for NK-based immunotherapy to eliminate residual tumor cells, prevent relapse and improve patient survival.

Original languageEnglish
Pages (from-to)27171-27196
Number of pages26
JournalOncotarget
Volume9
Issue number43
DOIs
Publication statusPublished - 1 Jun 2018

Fingerprint

Breast Neoplasms
Ligands
Messenger RNA
Survival
Natural Killer Cells
Neoplasms
Recurrence
KIR Receptors
Social Identification
Residual Neoplasm
Innate Immunity
Immunotherapy
Immune System
Up-Regulation
Lymph Nodes
Lymphocytes
Confidence Intervals
Neoplasm Metastasis
Phenotype

Keywords

  • Breast cancer
  • Kaplan-Meier plotter
  • Natural killer cells
  • NK receptor ligands
  • Prognosis

ASJC Scopus subject areas

  • Oncology

Cite this

Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients. / Abouelghar, Ali; Hasnah, Reem; Taouk, Ghina; Saad, Mohamad; Doldur, Manale.

In: Oncotarget, Vol. 9, No. 43, 01.06.2018, p. 27171-27196.

Research output: Contribution to journalArticle

@article{51ced95a4ccb4f3db2ef8675a278cdd0,
title = "Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients",
abstract = "Background: Natural killer (NK) cells are lymphocytes of the innate immune system that have potent cytotoxic activity against tumor cells. NK cell recognition and activity towards cancer cells are regulated by an integrated interplay between numerous inhibitory and activating receptors acting in concert to eliminate tumor cells expressing cognate ligands. Despite strong evidence supporting the role of NK cells in breast cancer (BC) control, BC still develops and progresses to form large tumors and metastases. A major mechanism of BC escape from NK immunity is the alteration of the expression of NK receptor ligands. The aim of this study was to determine whether NK receptor ligands' mRNA expression might influence prognosis in BC patients and whether these effects differ by molecular subtypes and clinicopathological features. Methods: We used the KM plotter platform to analyze the correlation between mRNA expression of 32 NK receptor ligands and relapse-free survival (RFS) and overall survival (OS) in 3951 and 1402 BC patients, respectively. The association with tumor subtypes and clinicopathological features was determined. BC samples were split into high and low expression groups according to the best cutoff value and the two patient cohorts were compared by Kaplan-Meier survival plots. The hazard ratios with 95{\%} confidence intervals and log rank P values were calculated and FDRadjusted for multiple testing correction. The data was considered to be statistically significant when FDR-adjusted P value < 0.05. Results: High mRNA expression of around 80{\%} of ligands for NK activating and inhibitory receptors associated with better RFS, which correlated with longer OS for only about half of the NK-activating ligands but for most NK-inhibitory ligands. Also, five NK-activating ligands correlated with worse prognosis. These prognostic values were differentially associated with the BC clinical criteria. In addition, the favorable prognostic influence of NK-activating ligands' upregulation, as a whole, was mainly significantly associated with HER2-positive and basal-like subtypes, lymph node positive phenotype, and high-grade tumors. Conclusions: NK receptor ligands appear to play an important role in defining BC patient prognosis. Identification of a group of patients with worse prognosis expressing high levels of NK-activating ligands and low levels of NK-inhibitory ligands makes them ideal potential candidates for NK-based immunotherapy to eliminate residual tumor cells, prevent relapse and improve patient survival.",
keywords = "Breast cancer, Kaplan-Meier plotter, Natural killer cells, NK receptor ligands, Prognosis",
author = "Ali Abouelghar and Reem Hasnah and Ghina Taouk and Mohamad Saad and Manale Doldur",
year = "2018",
month = "6",
day = "1",
doi = "10.18632/oncotarget.25506",
language = "English",
volume = "9",
pages = "27171--27196",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "43",

}

TY - JOUR

T1 - Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients

AU - Abouelghar, Ali

AU - Hasnah, Reem

AU - Taouk, Ghina

AU - Saad, Mohamad

AU - Doldur, Manale

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Natural killer (NK) cells are lymphocytes of the innate immune system that have potent cytotoxic activity against tumor cells. NK cell recognition and activity towards cancer cells are regulated by an integrated interplay between numerous inhibitory and activating receptors acting in concert to eliminate tumor cells expressing cognate ligands. Despite strong evidence supporting the role of NK cells in breast cancer (BC) control, BC still develops and progresses to form large tumors and metastases. A major mechanism of BC escape from NK immunity is the alteration of the expression of NK receptor ligands. The aim of this study was to determine whether NK receptor ligands' mRNA expression might influence prognosis in BC patients and whether these effects differ by molecular subtypes and clinicopathological features. Methods: We used the KM plotter platform to analyze the correlation between mRNA expression of 32 NK receptor ligands and relapse-free survival (RFS) and overall survival (OS) in 3951 and 1402 BC patients, respectively. The association with tumor subtypes and clinicopathological features was determined. BC samples were split into high and low expression groups according to the best cutoff value and the two patient cohorts were compared by Kaplan-Meier survival plots. The hazard ratios with 95% confidence intervals and log rank P values were calculated and FDRadjusted for multiple testing correction. The data was considered to be statistically significant when FDR-adjusted P value < 0.05. Results: High mRNA expression of around 80% of ligands for NK activating and inhibitory receptors associated with better RFS, which correlated with longer OS for only about half of the NK-activating ligands but for most NK-inhibitory ligands. Also, five NK-activating ligands correlated with worse prognosis. These prognostic values were differentially associated with the BC clinical criteria. In addition, the favorable prognostic influence of NK-activating ligands' upregulation, as a whole, was mainly significantly associated with HER2-positive and basal-like subtypes, lymph node positive phenotype, and high-grade tumors. Conclusions: NK receptor ligands appear to play an important role in defining BC patient prognosis. Identification of a group of patients with worse prognosis expressing high levels of NK-activating ligands and low levels of NK-inhibitory ligands makes them ideal potential candidates for NK-based immunotherapy to eliminate residual tumor cells, prevent relapse and improve patient survival.

AB - Background: Natural killer (NK) cells are lymphocytes of the innate immune system that have potent cytotoxic activity against tumor cells. NK cell recognition and activity towards cancer cells are regulated by an integrated interplay between numerous inhibitory and activating receptors acting in concert to eliminate tumor cells expressing cognate ligands. Despite strong evidence supporting the role of NK cells in breast cancer (BC) control, BC still develops and progresses to form large tumors and metastases. A major mechanism of BC escape from NK immunity is the alteration of the expression of NK receptor ligands. The aim of this study was to determine whether NK receptor ligands' mRNA expression might influence prognosis in BC patients and whether these effects differ by molecular subtypes and clinicopathological features. Methods: We used the KM plotter platform to analyze the correlation between mRNA expression of 32 NK receptor ligands and relapse-free survival (RFS) and overall survival (OS) in 3951 and 1402 BC patients, respectively. The association with tumor subtypes and clinicopathological features was determined. BC samples were split into high and low expression groups according to the best cutoff value and the two patient cohorts were compared by Kaplan-Meier survival plots. The hazard ratios with 95% confidence intervals and log rank P values were calculated and FDRadjusted for multiple testing correction. The data was considered to be statistically significant when FDR-adjusted P value < 0.05. Results: High mRNA expression of around 80% of ligands for NK activating and inhibitory receptors associated with better RFS, which correlated with longer OS for only about half of the NK-activating ligands but for most NK-inhibitory ligands. Also, five NK-activating ligands correlated with worse prognosis. These prognostic values were differentially associated with the BC clinical criteria. In addition, the favorable prognostic influence of NK-activating ligands' upregulation, as a whole, was mainly significantly associated with HER2-positive and basal-like subtypes, lymph node positive phenotype, and high-grade tumors. Conclusions: NK receptor ligands appear to play an important role in defining BC patient prognosis. Identification of a group of patients with worse prognosis expressing high levels of NK-activating ligands and low levels of NK-inhibitory ligands makes them ideal potential candidates for NK-based immunotherapy to eliminate residual tumor cells, prevent relapse and improve patient survival.

KW - Breast cancer

KW - Kaplan-Meier plotter

KW - Natural killer cells

KW - NK receptor ligands

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85048049495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048049495&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25506

DO - 10.18632/oncotarget.25506

M3 - Article

VL - 9

SP - 27171

EP - 27196

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -